Ophthalmology Times

Outlook Therapeutics has re-submitted its Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for ONS-5010 (bevacizumab-vikg) for the treatment of wet age-related macular degeneration (wet AMD). Read More: https://ow.ly/YwVx50V9j44

Artificial intelligence (AI) tools have a promising future for reliably detecting the presence and severity of amblyopia in pediatric patients. During the Fourth Annual Cleveland Eye Bank Foundation Virtual Vision Research Symposium, Fatema Ghasia, MD, discussed the different visual function defects in amblyopia, focusing on ocular motor deficits and how they can be used to create AI algorithms to detect amblyopia. She is an associate professor at Cleveland Clinic Cole Eye Institute and director of the Vision Neuroscience and Ocular Motility Laboratory at Cleveland Clinic in Ohio. Read More: https://ow.ly/z6HQ50V9iYm

The Australian Society of Ophthalmologists (ASO) has welcomed three new members to its Board of Directors in a move to strengthen advocacy and efficiency within the organization. Rahul Chakrabarti, MBBS (Hons), BMedSc (Hons), MD, MSurgED (Hons), FRANZCO, and Tricia Drew, MBBS, BMedSci (Hons) PhD, FRANZCO, will join representative Mark Grey, from Tasmania Read More: https://ow.ly/oU8r50V7GoC

Formycon AG announced in a press release that it has received approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for FYB203, a biosimilar to aflibercept (Eylea). FYB203 received MHRA approval for the treatment of neovascular age-related macular degeneration (nAMD), diabetic macular edema, macular edema following retinal vein occlusion, and visual impairment due to myopic choroidal neovascularization. Read More: https://ow.ly/RaHh50V7GhH

Bonnie Henderson, MD, founder and program director of the EnVision Summit, talked with Ophthalmology Times about the evolution of the conference and how it brings optometrists and ophthalmologists together to learn, discuss shared problems, and facilitate co-management in a family-friendly environment. Watch Now: https://ow.ly/Mwfg50V7FSf

It's been 2 weeks since the EnVision Summit in Puerto Rico, are you sure you didn't miss anything? Take a look at the comprehensive coverage from Ophthalmology Times!

Get a breakdown of the key steps in implanting the port delivery system in the next part of our series on novel retinal disease treatment. Aleksandra Rachitskaya, MD; and Jordan Graff, MD, FACS, discuss the whole process, emphasizing incision and closure techniques. Click here to watch now: https://ow.ly/4sXb50V4EnN #portdeliverysystem #retinaldiseases

With new and emerging technologies in quantitative ultrawidefield angiography (UWFA), Justis P. Ehlers, MD, believes that patients with diabetic eye disease can be treated more effectively by varying treatment approaches. During a presentation at the Fourth Annual Cleveland Eye Bank Foundation Virtual Vision Research Symposium,1 Ehlers offered insights into the value of quantitative UWFA in diabetic retinopathy. He reviewed machine learning-enhanced techniques to quantify diabetic retinopathy features, evaluating their link to disease severity and risk of progression. Read More: https://ow.ly/zfPs50V7FLQ

This AMD Awareness Month, we celebrate the ophthalmologists innovating on cutting edge treatments and management strategies for aged-related muscular degeneration. Explore the latest AMD content from Ophthalmology Times: https://ow.ly/GLsh50V8lt1 #AMD #Retina #Ophthalmology

Patients experiencing a high treatment burden with frequent anti-VEGF injections every 4 to 8 weeks are optimal candidates for the port delivery system. Learn how patients are selected for this treatment option and discover how it can reduce the number of clinic visits while maintaining therapeutic effectiveness. Click here to watch now: https://ow.ly/5fgk50UTgWw #antiVEGF #retinaldiseases #treatmentburden